Objective: Patient age is one important factor used to evaluate the risk in women with ASC-H (atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion). This finding may be associated with atrophic changes reflecting a hypoestrogenic status and suggests that body mass index (BMI) can affect the outcome of ASC-H smears in postmenopausal women. Study Design: We investigated the outcome of 154 postmenopausal women with an ASC-H smear and assessed relationships with BMI categories and serum estradiol levels. Results: In patients with higher BMI, an underlying squamous intraepithelial lesion (SIL) was more frequent than in patients with lower BMI, and a higher BMI was also associated with increased serum estradiol levels. When samples were classified by preparation method, these findings were more pronounced in liquid-based smears than in conventional smears. Principal component analysis using three factors (BMI, age and human papilloma virus status) revealed two distinct groups: those with a negative cervical smear and those with a smear result indicating SIL+. Conclusion: Hormonal alterations can affect the outcome of ASC-H smears, and BMI is one factor that should be considered when evaluating the risk associated with ASC-H smears in postmenopausal women.

1.
Solomon D, Davey D, Kurman R, Moriarty A, O’Connor D, Prey M, Raab S, Sherman M, Wilbur D, Wright T Jr, Young N: The 2001 Bethesda System – terminology for reporting results of cervical cytology. JAMA 2002;287:2114–2119.
2.
Cytryn A, Russomano FB, Camargo MJ, Zardo LM, Horta NM, Fonseca Rde C, Tristão MA, Monteiro AC: Prevalence of cervical intraepithelial neoplasia grades II/III and cervical cancer in patients with cytological diagnosis of atypical squamous cells when high-grade intraepithelial lesions (ASC-H) cannot be ruled out. Sao Paulo Med J 2009;127:283–287.
3.
Quddus MR, Sung CJ, Steinhoff MM, Lauchlan SC, Singer DB, Hutchinson ML: Atypical squamous metaplastic cells: reproducibility, outcome, and diagnostic features on ThinPrep Pap test. Cancer 2001;93:16–22.
4.
Selvaggi SM: Reporting of atypical squamous cells, cannot exclude a high-grade squamous intraepithelial lesion (ASC-H) on cervical samples: is it significant? Diagn Cytopathol 2003;29:38–41.
5.
Wright TC Jr, Cox JT, Massad LS, Twiggs LB, Wilkinson EJ: 2001 Consensus Guidelines for the management of women with cervical cytological abnormalities. JAMA 2002;287:2120–2129.
6.
Duncan LD, Jacob SV: Atypical squamous cells, cannot exclude a high-grade squamous intraepithelial lesion: the practice experience of a hospital-based reference laboratory with this new Bethesda system diagnostic category. Diagn Cytopathol 2005;32:243–246.
7.
Kietpeerakool C, Srisomboon J, Tantipalakorn C, Suprasert P, Khunamornpong S, Nimmanhaeminda K, Siriaunkgul S: Underlying pathology of women with ‘atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion’ smears, in a region with a high incidence of cervical cancer. J Obstet Gynaecol Res 2008;34:204–209.
8.
Louro AP, Roberson J, Eltoum I, Chhieng DC: Atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion. A follow-up study of conventional and liquid-based preparations in a high-risk population. Am J Clin Pathol 2003;120:392–397.
9.
Sung CO, Kim SR, Oh YL, Song SY: The use of p16(INK4A) immunocytochemistry in ‘atypical squamous cells which cannot exclude HSIL’ compared with ‘atypical squamous cells of undetermined significance’ in liquid-based cervical smears. Diagn Cytopathol 2010;38:168–171.
10.
Davey DD, Greenspan DL, Kurtycz DF, Husain M, Austin RM: Atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion: review of ancillary testing modalities and implications for follow-up. J Low Genit Tract Dis 2010;14:206–214.
11.
Yim KI, Kang YJ, Kim TE, Park G, Jung ES, Choi YJ, Lee KY, Kang CS, Lee A: The Usefulness of p16INK4a immunocytochemical staining in ASC-H patients. Korean J Pathol 2011;45:290–295.
12.
Bandyopadhyay S, Austin RM, Dabbs D, Zhao C: Adjunctive human papillomavirus DNA testing is a useful option in some clinical settings for disease risk assessment and triage of females with ASC-H Papanicolaou test results. Arch Pathol Lab Med 2008;132:19741981.
13.
Sung CO, Oh YL, Song SY: Cervical cytology of atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion (ASC-H); significances of age, human papillomavirus DNA detection, and previous cytology abnormality on follow-up outcomes. Eur J Obstet Gynecol Reprod Biol 2011;159:155–159.
14.
Repse-Fokter A, Takac I, Fokter SK: Postmenopausal vaginal atrophy correlates with decreased estradiol and body mass index and does not depend on the time since menopause. Gynecol Endocrinol 2008;24:399–404.
15.
Onuma K, Saad RS, Kanbour-Shakir A, Kanbour AI, Dabbs DJ: Clinical implications of the diagnosis ‘atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion’ in pregnant women. Cancer 2006;108:282–287.
16.
Patton AL, Duncan L, Bloom L, Phaneuf G, Zafar N: Atypical squamous cells, cannot exclude a high-grade intraepithelial lesion and its clinical significance in postmenopausal, pregnant, postpartum, and contraceptive-use patients. Cancer 2008;114:481–488.
17.
Castle PE, Fetterman B, Poitras N, Lorey T, Shaber R, Kinney W: Relationship of atypical glandular cell cytology, age, and human papillomavirus detection to cervical and endometrial cancer risks. Obstet Gynecol 2010;115:243–248.
18.
Chivukula M, Shidham VB: ASC-H in Pap test – definitive categorization of cytomorphological spectrum. Cytojournal 2006;3:14.
19.
Negri G, Menia E, Egarter-Vigl E, Vittadello F, Mian C: ThinPrep versus conventional Papanicolaou smear in the cytologic follow-up of women with equivocal cervical smears. Cancer 2003;99:342–345.
20.
Shiwaku K, Anuurad E, Enkhmaa B, Nogi A, Kitajima K, Shimono K, Yamane Y, Oyunsuren T: Overweight Japanese with body mass indexes of 23.0–24.9 have higher risks for obesity-associated disorders: a comparison of Japanese and Mongolians. Int J Obes Relat Metab Disord 2004;28:152–158.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.